WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H510310
CAS#: 4727-31-5
Description: Kartogenin induces the selective differentiation of multipotent mesenchymal stem cells (MSCs) into chondrocytes. Kartogenin binds to filamin A, and disrupts the specific interaction between filamin A and CBFβ (core-binding factor β subunit). Apparently, kartogenin induces chondrogenesis by regulating the nuclear localization of CBFβ.
Hodoodo Cat#: H510310
Name: Kartogenin
CAS#: 4727-31-5
Chemical Formula: C20H15NO3
Exact Mass: 317.11
Molecular Weight: 317.344
Elemental Analysis: C, 75.70; H, 4.76; N, 4.41; O, 15.13
Synonym: 2(Biphenyl4yl)carbamoylbenzoic acid 4Phenylphthalanilic acid (8CI) KGN.
IUPAC/Chemical Name: 2-([1,1'-biphenyl]-4-ylcarbamoyl)benzoic acid
InChi Key: SLUINPGXGFUMLL-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H15NO3/c22-19(17-8-4-5-9-18(17)20(23)24)21-16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13H,(H,21,22)(H,23,24)
SMILES Code: O=C(O)C1=CC=CC=C1C(NC2=CC=C(C3=CC=CC=C3)C=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 317.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Wang J, Zhou J, Zhang N, Zhang X, Li Q. A heterocyclic molecule kartogenin induces collagen synthesis of human dermal fibroblasts by activating the smad4/smad5 pathway. Biochem Biophys Res Commun. 2014 Jul 18;450(1):568-74. doi: 10.1016/j.bbrc.2014.06.016. Epub 2014 Jun 10. PubMed PMID: 24928394.
2: Mobasheri A. The future of osteoarthritis therapeutics: emerging biological therapy. Curr Rheumatol Rep. 2013 Dec;15(12):385. doi: 10.1007/s11926-013-0385-4. Review. PubMed PMID: 24170255; PubMed Central PMCID: PMC3837192.
3: Hayek A, Kerstetter-Fogle AE, Sachlos E, Bollenbach T. Kartogenin: a game-changer in regenerative medicine. Regen Med. 2012 Jul;7(4):475. PubMed PMID: 22993885.
4: Marini JC, Forlino A. Replenishing cartilage from endogenous stem cells. N Engl J Med. 2012 Jun 28;366(26):2522-4. doi: 10.1056/NEJMcibr1204283. PubMed PMID: 22738103.
5: Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, Meeusen S, Althage A, Cho CY, Wu X, Schultz PG. A stem cell-based approach to cartilage repair. Science. 2012 May 11;336(6082):717-21. doi: 10.1126/science.1215157. Epub 2012 Apr 5. PubMed PMID: 22491093.